A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair Compared With Perforomist Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair Compared With Perforomist Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Formoterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ACHIEVE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Sep 2017 According to a Circassia media release, based on the result from this study, company plans to file a New Drug Application (NDA) for Duaklir with the United States Food and Drug Administration (FDA) during the first half of 2018.
    • 22 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 17 Oct 2016 Planned End Date changed from 1 May 2017 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top